Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) was downgraded by equities researchers at TheStreet from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

Titan Pharmaceuticals (OTCMKTS:TTNP) opened at 4.60 on Thursday. The firm has a 50-day moving average price of $5.03 and a 200-day moving average price of $5.48. The stock has a market capitalization of $97.51 million and a PE ratio of 18.33. Titan Pharmaceuticals has a 52 week low of $2.57 and a 52 week high of $8.74.

Titan Pharmaceuticals (OTCMKTS:TTNP) last announced its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.01. Equities research analysts predict that Titan Pharmaceuticals will post $0.23 EPS for the current fiscal year.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.

Receive News & Stock Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.